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OBJECTIVE—This study investigated the hypothesis that base-
line calciﬁed coronary atherosclerosis may determine cardiovas-
cular disease events in response to intensive glycemic control
within the Veterans Affairs Diabetes Trial (VADT).
RESEARCH DESIGN AND METHODS—At baseline, 301 type
2 diabetic participants in the VADT, a randomized trial compar-
ing the effects of intensive versus standard glucose lowering on
cardiovascular events, had baseline coronary atherosclerosis
assessed by coronary artery calcium (CAC) measured by com-
puted tomography. Participants were followed over the 7.5-year
study for development of cardiovascular end points.
RESULTS—During a median follow-up duration of 5.2 years, 89
cardiovascular events occurred. Although intensive glucose-
lowering therapy did not signiﬁcantly reduce cardiovascular
events in the substudy cohort as a whole, there was evidence that
the response was modiﬁed by baseline CAC, as indicated by
signiﬁcant P values for treatment by log(CAC  1) interaction
terms in unadjusted and multivariable-adjusted models (0.01 and
0.03, respectively). Multivariable-adjusted hazard ratios (HRs)
for the effect of treatment indicated a progressive diminution of
beneﬁt with increasing CAC. Subgroup analyses were also con-
ducted for clinically relevant CAC categories: those above and
below an Agatston score of 100. Among those randomized to
intensive treatment, for the subgroup with CAC 100, 11 of 62
individuals had events, while only 1 of 52 individuals with CAC
100 had an event. The multivariable HR for intensive treatment
for those with CAC 100 was 0.74 (95% CI 0.46–1.20; P  0.21),
while for the subgroup with CAC 100, the corresponding HR
was 0.08 (0.008–0.77; P  0.03), with event rates of 39 and 4 per
1,000 person-years, respectively.
CONCLUSIONS—These data indicate that intensive glucose
lowering reduces cardiovascular events in those with less
extensive calciﬁed coronary atherosclerosis. Diabetes 58:
2642–2648, 2009
D
espite a wealth of epidemiologic data indicating
that poor glycemic control is associated with
increased risk for subsequent cardiovascular
disease (CVD) events (1–4), trials of glucose-
lowering therapy have not reduced the incidence of CVD
(5–12). The Veterans Affairs Diabetes Trial (VADT) was
one of several recent large prospective randomized studies
initiated to help clarify whether intensive glycemic control
would reduce development of macrovascular disease
events (13). After a median duration of follow-up of 5
years, the group receiving intensive glycemic control in
the VADT experienced no signiﬁcant reduction in CVD
events despite an average 1.5% lower median A1C through-
out the trial (14).
To more fully understand the relationships between
glycemic control, calciﬁed atherosclerosis, and CVD, a
substudy of subclinical atherosclerosis was conducted in
coordination with the VADT. This study, the Risk Factors,
Atherosclerosis, and Clinical Events in Diabetes (RACED)
study (15,16), examined coronary artery calcium (CAC) in
a subset of the VADT participants. A major goal of this
substudy was to determine whether the effect of intensive
glycemic control on CVD depended on the initial extent of
underlying atherosclerosis (as estimated by vascular cal-
cium) in participants.
RESEARCH DESIGN AND METHODS
Data for this study derive primarily from baseline examinations of participants
in the RACED study (15,16) and include incident CVD events during the VADT.
(Study staff and investigators in the RACED study are listed in the online
appendix, available at http://diabetes.diabetesjournals.org/cgi/content/full/
db09-0618/DC1). Sites that had access to appropriate computed tomography
scanning centers and were geographically representative of the national
distribution of VADT sites were selected for this substudy. The RACED study
included 324 patients with type 2 diabetes who were participating at seven
study sites (distributed across the southwest, midwest, and the southeast
regions of the U.S.) of the VADT and was approved by the institutional review
boards of these sites. All participants gave written informed consent. All
subjects enrolling into the VADT at the seven selected sites were asked to
participate in this substudy; of these, 95% agreed to receive CAC scans.
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study activities, and main results, have previously been reported (13,14).
Incident CVD events. The primary VADT end point was time to ﬁrst
occurrence of any of a composite of CVD events including documented
myocardial infarction; cerebrovascular accident; cardiovascular death; new or
worsening congestive heart failure; surgical intervention for cardiac, cerebro-
vascular, or peripheral vascular disease; inoperable coronary artery disease;
and amputation for ischemic gangrene. All reported end points were adjudi-
cated by an end points committee (13,14).
Coronary artery and abdominal aortic calcium scores. Coronary artery
calcium was measured using electron beam computed tomography cardiac
scanners (GE Imatron, South San Francisco, CA) as previously described
(15,16). Readers scoring calcium at the centralized reading center were
blinded to demographic and clinical information. A threshold of four contig-
uous pixels and 130 Hounsﬁeld units was used to identify calciﬁed lesions that
were scored using the algorithm developed by Agatston et al. (17). Total CAC
was determined by summing individual lesion scores from each of four
anatomic sites (left main, left anterior descending, circumﬂex, and right
coronary arteries). A calibration phantom was scanned under the chest of
each participant at each scanning center to calibrate the images to identical
standards, as previously described (15,16).
Statistical analyses. Statistical analyses were performed with SAS (version
9.2; SAS Institute, Cary, NC). Measures that were normally distributed are
reported as means  SD. Variables with a skewed distribution are reported as
median (interquartile range) or proportions. Signiﬁcant differences between
groups were assessed using t tests, Wilcoxon’s two-sample rank-sum test, or

2 tests, as appropriate. Prespeciﬁed goals of the RACED study included
determining whether baseline CAC [parameterized as log10(CAC  1) and by
clinical categories of CAC] inﬂuenced the relationship between treatment
assignment and CVD.
Kaplan-Meier curves were used to illustrate the relationship between
categories of calcium and CVD events by treatment groups. Patients without
an event were censored at their date of withdrawal from the study or of the
ﬁnal follow-up visit. To directly test effect modiﬁcation by CAC, the effects for
treatment, CAC [parameterized as log(CAC  1) or by CAC categories], and a
treatment-CAC interaction term were tested in unadjusted and adjusted Cox
models. Hazard ratios (HRs) for effects of intensive versus standard treatment
were then separately assessed within lower- and higher-CAC subgroups. To
limit the number of degrees of freedom for predictor variables to permit
adjustment for appropriate covariates, and because there were no events in
individuals assigned to intensive treatment who were within the lowest CAC
category, a post hoc decision was made to collapse the CAC categories into
clinically relevant categories (no/mild vs. moderate/severe disease) by dichoto-
mizing at an Agatston score of 100 (18,19). To avoid overﬁtting of ﬁnal regression
models, prespeciﬁed baseline covariates were limited to age, ethnicity, and
variables (diabetes duration, smoking, prior CVD, hypertension, glycemic control,
and lipid levels) for which the literature strongly supports a relationship with
either CVD events or CAC. Adding other variables (BMI, serum creatinine, urinary
albumin/creatinine, blood pressure, and medication use) to those models did not
meaningfully alter results concerning the CAC-treatment interaction. All reported
P values are two sided and not adjusted for multiple testing.
RESULTS
For the 301 participants with available baseline CAC
scans, the mean duration of diabetes was 12.1  8.0 years
and mean age 61.0  9.0 years, most subjects were male
(95%) and non-Hispanic white (65%), and prevalence of
hypertension (79%) and prior CVD (38%) was high. Clinical
characteristics for the 301 RACED participants were gen-
erally similar to those for the other VADT participants
(Table 1). The minimum CAC Agatston score was 0
(present in 16%), while 25th, 50th (median), and 75th
percentiles for CAC were 23, 276, and 872, respectively.
Clinical characteristics by treatment group are shown in
Table 2. The intensive group had lower triglycerides and
higher HDL cholesterol (P  0.05 for both) but had similar
levels of other risk factors. As in the VADT (14), A1C levels in
intensive and standard groups in the RACED substudy were
well separated after 1 year (P  0.01), and the difference
averaged 1.5% units throughout the study (Fig. 1).
In the RACED cohort, a total of 89 participants experi-
enced primary events over a median follow-up duration of
5.2 years. These events included 30 coronary, carotid, or
peripheral revascularizations, 19 episodes of congestive
heart failure, 16 myocardial infarctions, 10 strokes, 9 CVD
deaths, 3 ischemic amputations, and 2 cases of severe but
inoperable coronary artery disease. RACED participants
who suffered a CVD event during follow-up were older,
more likely to be non-Hispanic white, and had a longer
history of diabetes, a greater prevalence of prior CVD, and
lower HDL cholesterol (all P  0.05). The median CAC was
signiﬁcantly higher in those who had an event (P  0.01).
Other characteristics did not differ signiﬁcantly between
those who did or did not develop clinical events. In this
TABLE 1
Comparison of clinical characteristics for RACED participants
and for VADT participants who did not participate in RACED
RACED VADT P
n 301 1,490
Age (years) 61  96 0  9 0.19
Male 94.7 97.6 0.01
NHW 65 61 0.18
Duration of diabetes (years) 12.1  8.0 11.4  7.4 0.15
BMI (kg/m
2) 31.5  4.3 31.2  4.4 0.24
History of CVD 38 41 0.33
Current smoker 15 17 0.37
History of hypertension 79 71 0.01
SBP (mmHg) 131  17 132  17 0.77
DBP (mmHg) 75  10 76  10 0.04
A1C 9.3  1.4 9.5  1.6 0.04
Total cholesterol (mmol/l) 4.65  0.98 4.76  1.27 0.17
HDL cholesterol (mmol/l) 0.96  0.26 0.93  0.26 0.18
LDL cholesterol (mmol/l) 2.69  0.80 2.79  0.83 0.09
Triglycerides (mmol/l) 2.27  1.48 2.42  3.33 0.46
Data are means  SD or percent unless otherwise indicated. P values
are from independent-samples t tests or Wilcoxon or 
2 tests, as
appropriate. DBP, diastolic blood pressure; NHW, non-Hispanic
white; SBP, systolic blood pressure.
TABLE 2
Comparison of clinical characteristics of RACED participants
according to VADT treatment assignment
Standard Intensive P
n 159 142
Age (years) 61  96 1  9 0.89
NHW 69 62 0.23
Duration of diabetes (years) 12.0  7.7 12.2  8.3 0.77
BMI (kg/m
2) 31.7  4.3 31.3  4.4 0.47
History of CVD 39 37 0.67
Current smoker 15 15 0.94
History of hypertension 78 81 0.49
SBP (mmHg) 132  18 130  16 0.32
DBP (mmHg) 75  10 75  11 0.72
A1C 9.3  1.4 9.3  1.5 0.94
Total cholesterol (mmol/l) 4.64  0.96 4.67  1.01 0.73
HDL cholesterol (mmol/l) 0.92  0.27 0.98  0.26 0.03
LDL cholesterol (mmol/l) 2.65  0.79 2.77  0.79 0.23
Triglycerides (mmol/l) 2.48  1.64 2.04  1.24 0.01
Statin use 57 64 0.23
TZD use 12 10 0.56
ASA use 86 86 0.95
BP medication 91 89 0.61
Data are means  SD or percent unless otherwise indicated. ASA,
aspirin; BP, blood pressure; DBP, diastolic blood pressure; NHW,
non-Hispanic white; SBP, systolic blood pressure; TZD, thiazo-
lidinedione. P values are from independent-samples t tests or Wil-
coxon or 
2 tests, as appropriate.
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treatment group was not signiﬁcant (unadjusted HR 0.72
[0.47 – 1.10]; P  0.13), and was comparable to that found
for the entire VADT (14).
To test whether baseline CAC modiﬁed the inﬂuence of
intensive glucose management (as assigned within the
VADT) on future CVD events, we considered models
including interactions between treatment and calcium
[parameterized as log(CAC  1) or dichotomized at 100].
In models including log(CAC  1) or calcium categories
(0–100 and 100), treatment, and calcium-by-treatment
interaction but no adjustment for other covariates, the P
values for interaction were 0.01 and 0.05, respectively,
indicating that effects of intensive versus standard glucose
management were modiﬁed by baseline CAC. After adjust-
ment for relevant covariates, P values for interaction
terms in corresponding multivariable models were 0.03
and 0.07, respectively, providing further support for differ-
ential effects of treatment according to level of CAC. A
bootstrap analysis (using 2,000 samples) was also per-
formed and identiﬁed the treatment, baseline CAC, inter-
action of baseline CAC with treatment, and prior CVD
history as the four most important predictors of CVD
events, each occurring in 73% of the repeated samplings
(data not shown).
Kaplan-Meier curves for time to ﬁrst CVD primary event
(Fig. 2) by treatment group for each of the four categories
of CAC illustrate the modiﬁcation of treatment effect with
changes in baseline CAC. In the lowest two categories of
calcium (CAC 0–10 and 11–100), participants randomized
to receive intensive treatment had a CVD risk that was
substantially lower than those randomized to standard
therapy (P  0.03 for those with CAC 0–10 and P  0.12
for those with CAC 11–100). In fact, with these two
low-CAC groups combined, a very low proportion of those
receiving intensive therapy developed events (only 1 of 52
participants during follow-up; median time to event 5.2
years and maximum 6 years). In comparison, with the
same two groups combined, a much larger proportion (11
of 62 participants) in the standard arm had an event. This
corresponded to event rates of 4 and 39 per 1,000 person-
years for those receiving intensive and standard therapy,
respectively. The event types by treatment group are
shown in the supplemental table in the online appendix. A
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FIG. 2. Kaplan-Meier curves for time to primary macrovascular end point by clinical categories of CAC (0–10 [A], 11–100 [B], 101–400 [C], and
>400[D]) in those randomized to the standard (Std) or intensive (Int) therapy arm. Differences between treatment groups were signiﬁcant in
A (P  0.03). Shown above the x-axes are the total numbers of participants at risk at baseline and the beginning of each follow-up year through
year 6.
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intensive and standard treatment arms in the combined
lower CAC categories revealed no signiﬁcant differences
(Table 3), and any potentially relevant differences in these
variables were accounted for in subsequent multivariable
models. Similar results were present when individuals
without previous CVD were excluded. In contrast, Kaplan-
Meier curves for participants in the two higher CAC
categories (101–400 and 400) demonstrated similar lev-
els of CVD risk in both treatment groups. This occurred
despite the fact that at baseline, triglyceride levels were
lower and HDL cholesterol levels higher in the intensive
treatment group (Table 3). The distribution of CVD events
(supplemental Table 1) was similar between treatment
groups in the higher two CAC categories.
Figure 3 graphically displays HRs and CIs for the effect
of intensive treatment for multivariable models ﬁtted
separately for subgroups with higher (100) and lower
(100) CAC. For the subgroup with higher CAC, the
multivariable HR for the effect of treatment was 0.74 (95%
CI 0.46–1.18; P  0.21), while for those with lower CAC,
the multivariable HR for treatment was 0.08 (0.008–0.77;
P  0.03). The magnitude of beneﬁt of treatment across
the range of CAC scores was further examined by esti-
mating HRs for treatment from a multivariable model
including age, ethnicity, diabetes duration, history of hy-
pertension, history of smoking, prior CVD history, total
and HDL cholesterol, and A1C as covariates and, addition-
ally, log(CAC  1), treatment, and calcium-by-treatment
interaction. This analysis with CAC parameterized on the
log scale was performed with data for all participants. This
approach revealed that the beneﬁt of intensive treatment
diminished in a progressive manner across selected CAC
scores of 0, 10, and 100, with HRs of 0.07 (0.01–0.55; P 
0.01), 0.16 (0.04–0.61; P  0.01), and 0.34 (0.16–0.73; P 
0.01), and was completely absent at very high CAC scores
(e.g., an HR of 0.75 [95% CI 0.47–1.19; P  0.22] for a CAC
score of 1,000). Additional sensitivity analyses, using CAC
coded as tertiles (0–57, 58–641, and 641) or as three
clinical categories (0–100, 101–400, and 400), yielded
consistent results and demonstrated that the beneﬁt of
intensive glycemic control for CVD outcomes was appar-
ent only for individuals in the lowest CAC category.
DISCUSSION
The major novel ﬁnding of this study was that in a subset
of VADT participants, the beneﬁt of intensive glycemic
control on CVD outcomes was greater for those with lower
CAC. Models with CAC parameterized either as a contin-
uous variable [log(CAC  1)] or by categories of CAC,
whether or not adjustment was made for multiple covari-
ates, provided consistent evidence for the presence of a
signiﬁcant treatment-calcium interaction. These results
were also observed when the analysis was limited to
RACED subjects without a baseline history of CVD. Both
the continuous model and the model based on the catego-
ries of CAC indicated that intensive glucose therapy
reduced future CVD events predominantly in participants
with less extensive atherosclerotic disease. This translated
to a nearly 90% reduction in incidence of CVD events
in those with very low CAC (subgroup with CAC 100
where the median CAC was 5 or with CAC 10 in the log
model). In this low-CAC group, the estimated number
needed to treat with intensive glucose lowering to prevent
one CVD event was 29. Less beneﬁt was observed at higher
levels of CAC.
These RACED substudy results suggest that intensive
glycemic control may not be effective in those with more
advanced vascular disease. Based on the CAC distribution
in this VADT subset, nearly 40% of the full VADT cohort
presumably would have had extensive atherosclerosis
TABLE 3
Comparison of clinical characteristics for RACED participants with lower (100) or higher (100) CAC according to VADT treatment
assignment
Lower CAC
P
Higher CAC
P Standard Intensive Standard Intensive
n 62 52 97 90
Age (years) 57  95 7  9 0.74 64  96 4  9 0.90
NHW 58 48 0.29 75 70 0.42
Duration of diabetes (years) 10.2  7.2 9.4  7.8 0.57 13.12  7.2 13.9  7.8 0.49
BMI (kg/m
2) 31.8  4.0 30.9  4.6 0.28 31.6  4.5 31.5  4.3 0.92
History of CVD 16 6 0.08 54 54 0.91
Current smoker 18 15 0.74 13 14 0.84
History of hypertension 65 75 0.23 86 84 0.72
SBP (mmHg) 133  18 131  16 0.62 132  18 130  17 0.39
DBP (mmHg) 78  10 79  11 0.56 73  97 3  10 0.88
A1C 9.6  1.4 9.5  1.5 0.88 9.1  1.3 9.1  1.4 0.90
Total cholesterol (mmol/l) 4.84  1.16 4.94  1.11 0.70 4.50  0.78 4.53  0.92 0.83
HDL cholesterol (mmol/l) 0.96  0.28 1.06  0.31 0.12 0.89  0.25 1.06  0.21 0.11
LDL cholesterol (mmol/l) 2.79  0.93 2.90  0.88 0.52 2.57  0.67 2.68  0.72 0.28
Triglycerides (mmol/l) 2.40  1.70 2.05  1.00 0.21 2.53  1.61 2.03  1.36 0.02
Statin use 52 54 0.81 61 70 0.19
TZD use 13 8 0.37 11 11 0.96
ASA use 87 85 0.71 86 87 0.83
BP medication 89 85 0.52 93 92 0.88
CAC (Agatston units) 20  26 18  26 0.64 1,106  1,384 1,106  1,146 0.99
Data are means  SD or percent unless otherwise indicated. ASA, aspirin; BP, blood pressure; DBP, diastolic blood pressure; NHW,
non-Hispanic white; SBP, systolic blood pressure; TZD, thiazolidinedione. P values are from independent-samples t tests or Wilcoxon or 
2
tests, as appropriate.
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100 at study entry. Thus, intensive glycemic control
would not be expected to be beneﬁcial in that large
portion of the VADT cohort which had more extensive
atherosclerosis. Consistent with this, the reduction in CVD
observed in the intensive treatment group in the overall
VADT (unadjusted HR 0.88 [95% CI 0.74–1.05]; P  0.14)
was not signiﬁcant and was comparable with that found
for all subjects in this substudy (0.72 [0.47–1.10]; P  0.13).
The modestly better outcome in the RACED cohort (com-
pared with that in the overall VADT study) may reﬂect a
different composition of participants or more intensive
glucose lowering, but this is not apparent from the base-
line clinical characteristics (Table 1) or A1C values ob-
served during the study (Fig. 1). Moreover, despite the
slight trend for a more favorable outcome in response to
intensive glucose reduction in the RACED cohort, those
with higher levels of CAC received substantially less
beneﬁt from intensive therapy than did those with lower
CAC. This conclusion seems to provide a plausible inter-
pretation of the results from the ACCORD and ADVANCE
trials (11,12). Both of those studied populations were older
and included participants with established diabetes and
one or more CVD risk factors, suggesting that most of the
participants in these studies may also have had relatively
advanced atherosclerosis. This is supported by the fact
that nearly one-third of both cohorts had a history of CVD
at study entry. Therefore, inferring from the current re-
sults, both the ACCORD and ADVANCE cohorts may also
have had such extensive atherosclerosis that no beneﬁt
from intensive glucose lowering was observed.
The current RACED study does, however, indicate that
intensive glycemic therapy may be effective in those with
less extensive coronary atherosclerosis. Consistent with
these results, two subgroups of subjects in the ACCORD
study that could reasonably be expected to have reduced
atherosclerosis—those with lower baseline A1C values
(8%) and those with no prior history of CVD—demon-
strated signiﬁcant reductions in the primary composite
CVD end point in response to intensive glycemic control
(11). This may also explain the more favorable results in
the UK Prospective Diabetes Study, which evaluated im-
proved glucose control in patients with newly diagnosed
diabetes (6,20). An important implication of these ﬁndings
is that it may be possible to identify patients who may
obtain greater CVD beneﬁt from intensive glucose-lower-
ing therapy while preserving quality of life and avoiding
unnecessary expenditure of resources and risk of adverse
side effects of intensive treatment in those less likely to
beneﬁt.
An important, but unanswered, question is why glucose
lowering is less effective in reducing CVD events in
individuals with more advanced atherosclerosis. Although
numerous mechanisms have been implicated in the initia-
tion and development of atherosclerosis in diabetes, there
is less information about which processes may be respon-
sive to lowered glucose. One may speculate that when
sufﬁcient plaque development has occurred, the presence
Persons        Events 
CAC Subgroups
High (>100) CAC              180               73  
Low (≤ 100) CAC              113               12
Specific CAC Levels;
CAC Modeled on the  293 85
Log Scale                                   
CAC = 0
CAC = 10
CAC = 100
CAC = 1000
Intensive Better 
HR for Intensive vs. Standard Treatment
P-Values
0.21
0.03
0.01
0.22
0.008
0.005
0.0           0.5           1.0           1.5
FIG. 3. HRs (95% CI) for effect of treatment (intensive vs. standard) in multivariable-adjusted models. Boxes represent HRs, and lines indicate
95% CI. P values indicate the signiﬁcance of treatment effect in the indicated models. The treatment effect was estimated for high- and low-CAC
subgroups separately (upper portion of ﬁgure) or for speciﬁc CAC scores (lower portion of ﬁgure) within a multivariable model including
log(CAC  1) as a continuous variable, treatment, and the calcium-treatment interaction effect. Multivariable models included age, ethnicity,
diabetes duration, history of hypertension, history of smoking, prior CVD history, total and HDL cholesterol, and A1C as covariates.
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altered immune cell signaling may generate a self-
propagating process that maintains atherogenesis even in
the face of improved glucose control. Alternatively,
chronic hyperglycemia leads to advanced glycation end
product formation and extensive protein cross-linking—a
process that is not readily reversible, increases with age,
and is enhanced by oxidative stress (21). For older indi-
viduals with a long history of diabetes, the past burden of
hyperglycemia and advanced glycation end product forma-
tion is presumably extensive and may have long-term
negative “legacy” effects (21,22). Although glucose lower-
ing may prevent new advanced glycation end product
formation and limit new vascular injury, 3–5 years of
intensive glycemic control as occurs during clinical trials
is presumably insufﬁcient to reverse the accumulated
vascular damage from decades of hyperglycemia or other
metabolic abnormalities.
Several limitations of this study deserve mention. The
number of incident CVD events in this substudy of the
VADT is relatively modest. Although we accounted for
the available cardiovascular risk factors that appeared to
be relevant determinants of CVD events in this cohort, it is
possible that other useful predictors may exist and were
not examined. However, comparison of risk factors and
relevant medication use between standard and intensive
groups in RACED participants with lower CAC at baseline
revealed similar levels of risk factors (Table 3), and
treatment effects persisted in multivariable (i.e., adjusted)
models. Although examination of baseline CAC (using
either log CAC or clinical CAC categories) as an effect
modiﬁer of glycemic control was a prespeciﬁed aim of this
study, the decision to dichotomize CAC at 100 was deter-
mined post hoc to facilitate analysis in the context of the
very low number of events in those with low CAC. The cut
point of 100 Agatston units for CAC is clinically used to
stratify CVD risk and reﬂected expected differences in
incidence of CVD between the low and high CAC catego-
ries within the RACED cohort (18,19). Moreover, when
CAC was considered as a continuous variable, which ﬁt
the data somewhat better than the CAC dichotomization
approach, there was a progressive increase in beneﬁt of
intensive treatment with decreasing values of CAC, and
again, no treatment beneﬁt was seen in those at the highest
CAC scores. Additional sensitivity analyses, using CAC
expressed either as tertiles or as three clinical categories
(0–100, 101–400, and 400) also demonstrated that the
beneﬁt of intensive glycemic control for CVD was present
only for individuals within the lowest CAC category.
Despite these consistent results, it is important that these
novel ﬁndings be conﬁrmed in larger diabetes cohorts and
in studies with a greater proportion of female participants.
In summary, these data provide support for the concept
that intensive glucose-lowering therapy may be most ef-
fective in reducing CVD in those with less extensive
coronary atherosclerosis.
ACKNOWLEDGMENTS
Financial support for this work was provided by the
Cooperative Studies Program of the Department of Veter-
ans Affairs Ofﬁce of Research and Development, National
Institutes of Health Grant RO1067690 (to P.D.R.), the
Kronos Research Institute, and clinical research awards
from the American Diabetes Association (to P.D.R.).
J.H.S. received grant support from Roche Pharmaceuti-
cals. C.A. received grants from GlaxoSmithKline, sanoﬁ-
aventis, Amylin, Novo Nordisk, Roche Diagnostics, Kos
Pharmaceuticals, the National Institutes of Health Na-
tional Eye Institute and the American Diabetes Associa-
tion, and speaker fees from sanoﬁ-aventis and Takeda. No
other potential conﬂicts of interest relevant to this article
were reported.
Parts of this study were presented in abstract form at
the 68th Scientiﬁc Sessions of the American Diabetes
Association, San Francisco, California, 6–10 June 2008.
REFERENCES
1. Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA, Hadden
D, Turner RC, Holman RR. Association of glycaemia with macrovascular
and microvascular complications of type 2 diabetes (UKPDS 35): prospec-
tive observational study. BMJ 2000;321:405–412
2. Khaw KT, Wareham N, Bingham S, Luben R, Welch A, Day N. Association
of hemoglobin A1c with cardiovascular disease and mortality in adults: the
European prospective investigation into cancer in Norfolk. Ann Intern Med
2004;141:413–420
3. Selvin E, Marinopoulos S, Berkenblit G, Rami T, Brancati FL, Powe NR,
Golden SH. Meta-analysis: glycosylated hemoglobin and cardiovascular
disease in diabetes mellitus. Ann Intern Med 2004;141:421–431
4. Laakso M. Hyperglycemia and cardiovascular disease in type 2 diabetes.
Diabetes 1999;48:937–942
5. UK Prospective Diabetes Study (UKPDS) Group. UKPDS: intensive blood-
glucose control with sulphonylureas or insulin compared with conven-
tional treatment and risk of complications in patients with type 2 diabetes
(UKPDS 33). Lancet 1998;352:837–853
6. UKPDS Group. Effect of intensive blood-glucose control with metformin
on complications in overweight patients with type 2 diabetes (UKPDS 34).
Lancet 1998;352:854–865
7. Duckworth WC, McCarren M, Abraira C. Glucose control and cardiovas-
cular complications: the VA Diabetes Trial. Diabetes Care 2001;24:942–945
8. Stettler C, Allemann S, Juni P, Cull CA, Holman RR, Egger M, Krahenbuhl S,
Diem P. Glycemic control and macrovascular disease in types 1 and 2 diabetes
mellitus: meta-analysis of randomized trials. Am Heart J 2006;152:27–38
9. Leibel B. An analysis of the University Group Diabetes Study Program:
data results and conslusions. Can Med Assoc J 1971;105:292–294
10. Abraira C, Colwell JA, Nuttall FQ, Sawin CT, Nagel NJ, Comstock JP,
Emanuele NV, Levin SR, Henderson W, Lee HS. Veterans Affairs Cooper-
ative Study on glycemic control and complications in type II diabetes (VA
CSDM): results of the feasibility trial: Veterans Affairs Cooperative Study in
Type II Diabetes. Diabetes Care 1995;18:1113–1123
11. Gerstein HC, Miller ME, Byington RP, Goff DC Jr, Bigger JT, Buse JB,
Cushman WC, Genuth S, Ismail-Beigi F, Grimm RH Jr, Probstﬁeld JL,
Simons-Morton DG, Friedewald WT. Effects of intensive glucose lowering
in type 2 diabetes. N Engl J Med 2008;358:2545–2559
12. Patel A, MacMahon S, Chalmers J, Neal B, Billot L, Woodward M, Marre M,
Cooper M, Glasziou P, Grobbee D, Hamet P, Harrap S, Heller S, Liu L,
Mancia G, Mogensen CE, Pan C, Poulter N, Rodgers A, Williams B,
Bompoint S, de Galan BE, Joshi R, Travert F. Intensive blood glucose
control and vascular outcomes in patients with type 2 diabetes. N Engl
J Med 2008;358:2560–2572
13. Abraira C, Duckworth W, McCarren M, Emanuele N, Arca D, Reda D,
Henderson W. Design of the cooperative study on glycemic control and
complications in diabetes mellitus type 2: Veterans Affairs Diabetes Trial.
J Diabetes Complications 2003;17:314–322
14. Duckworth W, Abraira C, Moritz T, Reda D, Emanuele N, Reaven PD, Zieve
FJ, Marks J, Davis SN, Hayward R, Warren SR, Goldman S, McCarren M,
Vitek ME, Henderson WG, Huang GD. Glucose control and vascular
complications in veterans with type 2 diabetes. N Engl J Med 2009;360:
129–139
15. Reaven PD, Sacks J. Coronary artery and abdominal aortic calciﬁcation are
associated with cardiovascular disease in type 2 diabetes. Diabetologia
2005;48:379–385
16. Reaven PD, Sacks J. Reduced coronary artery and abdominal aortic
calciﬁcation in Hispanics with type 2 diabetes. Diabetes Care 2004;27:
1115–1120
17. Agatston AS, Janowitz WR, Hildner FJ, Zusmer NR, Viamonte M Jr,
Detrano R. Quantiﬁcation of coronary artery calcium using ultrafast
computed tomography. J Am Coll Cardiol 1990;15:827–832
18. Greenland P, Bonow RO, Brundage BH, Budoff MJ, Eisenberg MJ, Grundy
SM, Lauer MS, Post WS, Raggi P, Redberg RF, Rodgers GP, Shaw LJ, Taylor
P.D. REAVEN AND ASSOCIATES
diabetes.diabetesjournals.org DIABETES, VOL. 58, NOVEMBER 2009 2647AJ, Weintraub WS. ACCF/AHA 2007 clinical expert consensus document
on coronary artery calcium scoring by computed tomography in global
cardiovascular risk assessment and in evaluation of patients with chest
pain: a report of the American College of Cardiology Foundation Clinical
Expert Consensus Task Force (ACCF/AHA Writing Committee to Update
the 2000 Expert Consensus Document on Electron Beam Computed
Tomography) developed in collaboration with the Society of Atheroscle-
rosis Imaging and Prevention and the Society of Cardiovascular Computed
Tomography. J Am Coll Cardiol 2007;49:378–402
19. Rumberger JA. Coronary artery calcium scanning using computed tomog-
raphy: clinical recommendations for cardiac risk assessment and treat-
ment. Semin Ultrasound CT MR 2008;29:223–229
20. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up
of intensive glucose control in type 2 diabetes. N Engl J Med 2008;359:
1577–1589
21. Yan SF, Ramasamy R, Naka Y, Schmidt AM. Glycation, inﬂammation, and
RAGE: a scaffold for the macrovascular complications of diabetes and
beyond. Circ Res 2003;93:1159–1169
22. Del Prato S. Megatrials in type 2 diabetes: from excitement to frustration?
Diabetologia 2009;52:1219–1226
INTENSIVE GLUCOSE LOWERING REDUCES CVD EVENTS
2648 DIABETES, VOL. 58, NOVEMBER 2009 diabetes.diabetesjournals.org